Italian pharmaceutical company, Angelini Pharma – part of the private Italian Angelini Group – has announced that it is looking to acquire Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from Central Nervous System (CNS).
Transaction overview
This is an all-cash deal for a total valuation of up to $960M (approx €782.5M). Following regulatory approval, the company will be paid $610M (approx €497.2M). Subsequently, a further $350M (approx €285.3M) will be paid, once Cenobamante – developed by Korea’s SK Biopharmaceuticals – reaches certain revenue targets.